<DOC>
	<DOCNO>NCT01848639</DOCNO>
	<brief_summary>This study design etablish effect spironolactone comparison placebo composite endpoint nonfatal Myocardial Infarction ( MI ) acute coronary syndrome , hospitalization heart failure , nonfatal stroke cardiovascular-induced death . The primary endpoint time onset first incident .</brief_summary>
	<brief_title>ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial</brief_title>
	<detailed_description>- During run-in period : Spironolactone initially administer per o 25 mg dose per two day practice session , three time per week - Patients randomize ( spironolactone vs. placebo ) titrate one month maximum single dose 25 mg/d - However kalemia great equal 5.5 mmol / l twice run-in period day randomization , patient wo n't randomize . - A pre-specified algorithm management risk incident hyperkalemia follow , include dose adjustment , temporary cessation study treatment , addition usual dietary measure use chelate resin low-potassium dialysis bath - Patients follow mean 2 year .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Written inform consent Health insurance beneficiary Men woman , hemodialysis least 45 day endstage renal disease regardless aetiology include diabetes , least 3 hemodialysis session per week AND present least one follow comorbidities CV risk factor : leave ventricular mass &gt; 130 g/m2 men 100 g/m2 woman measure twelve month precede inclusion leave ventricular ejection fraction &lt; 40 % measure twelve month precede inclusion diabetes history Cardiovascular disease : coronary artery disease , symptomatic low limb peripheral arterial disease , carotid renal artery stenosis &gt; 50 % , stroke , hospitalization heart failure CRP &gt; 5 mg / l 3 month without infectious neoplastic disease document progress history hypersensitivity spironolactone galactose intolerance Lapp lactase deficiency malabsorption glucose galactose hyperkalemia &gt; 5.5 mmol/l two week prior enrolment history unscheduled hemodialysis hyperkalemia last six month hospitalization hyperkalemia last six month patient imperative indication combination ACEI sartan renin inhibitor ( authorize separately ) , NSAIDS , Cox2 inhibitor kidney transplant schedule within year symptomatic interdialytic hypotension acute systemic disease uncompensated hypothyroidism acute hyperthyroidism prior concomitant clinical condition compromise inclusion , discretion investigator cardiac transplant severe uncontrolled arrhythmia stroke within 3 month prior enrolment acute coronary syndrome previous month inclusion recent ( 1 month ) plan coronary revascularization angioplasty recent ( 3 month ) plan cardiovascular surgery ( exclude HD vascular access ) non menopausal woman without effective contraceptive method pregnancy , breastfeed planning pregnancy within 2 year non compliance protect adult SBP &gt; 200 mmHg and/or DBP &gt; 110 mmHg Concomitant treatment stop another potassiumsparing diuretic , potassium supplement , AINS Cox 2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>chronic kidney disease</keyword>
	<keyword>end-stage renal disease</keyword>
	<keyword>hemodialysis ( ESRD )</keyword>
	<keyword>cardiovascular morbimortality</keyword>
	<keyword>aldosterone antagonist</keyword>
	<keyword>spironolactone</keyword>
</DOC>